A pilot randomized double-blind placebo-controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin

被引:21
|
作者
Wazait, HD
Patel, HR
van der Meulen, JHP
Ghei, M
Al-Buheissi, S
Kelsey, M
Miller, RA
Emberton, M
机构
[1] Royal Coll Surgeons England, Clin Effectiveness Unit, London WC2A 3PN, England
[2] Whittington Hosp NHS Trust, Dept Urol, London, England
[3] Whittington Hosp NHS Trust, Dept Microbiol, London, England
[4] London Sch Hyg & Trop Med, London WC1, England
关键词
catheter; urinary tract infections; nosocomial infection;
D O I
10.1111/j.1464-410X.2004.05102.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To assess if a short course of antibiotics starting at the time of the removing a short-term urethral catheter decreases the incidence of subsequent urinary tract infection (UTI). PATIENTS AND METHODS Patients across specialities with a urethral catheter in situ for greater than or equal to 48 h and less than or equal to 7 days were recruited at the time of catheter removal. Patients were excluded if they had had recent genitourinary surgery or were on antibiotics. Eligible patients were randomly assigned to a 48-h course of either ciprofloxacin or placebo tablets starting 2 h before catheter removal. A catheter specimen of urine was obtained before the start of the trial medication. The follow-up was at 7 and 14 days after catheter removal, with a questionnaire for UTI symptoms, and a mid-stream urine sample was taken. RESULTS Forty-eight patients were recruited and had a complete follow-up (25 received ciprofloxacin and 23 placebo). Of the ciprofloxacin group, four patients (16%) had a UTI at the follow-up after catheter removal, and two were symptomatic. The UTI in two patients (including one of those symptomatic) was newly developed after catheter removal; the other two UTIs were a result of failure to resolve a catheter-associated UTI. All these UTIs in the ciprofloxacin group were resistant to ciprofloxacin. Of the placebo group, three patients (13%) had a UTI at the follow-up after removal, and one patient was symptomatic. The UTI, newly developed after catheter removal, was resistant to ciprofloxacin. The other two patients were asymptomatic; their UTIs were a result of failure to resolve a catheter-associated UTI, and one was resistant to ciprofloxacin. CONCLUSIONS The risk of UTI (both symptomatic and asymptomatic) after removing a urethral catheter is real, even in absence of catheter-associated UTI before removal. UTIs occurring after removing a short-term urinary catheter had a high rate of resistance to ciprofloxacin. There was no detectable significant benefit in using prophylactic ciprofloxacin to reduce the UTI rate after catheter removal.
引用
收藏
页码:1048 / 1050
页数:3
相关论文
共 50 条
  • [31] Double-blind randomized placebo-controlled trial of sibutramine
    Bray, GA
    Ryan, DH
    Gordon, D
    Heidingsfelder, S
    Cerise, F
    Wilson, K
    OBESITY RESEARCH, 1996, 4 (03): : 263 - 270
  • [32] CIPROFLOXACIN VERSUS CINOXACIN IN THERAPY OF URINARY-TRACT INFECTIONS - A RANDOMIZED, DOUBLE-BLIND TRIAL
    GOLDSTEIN, EJC
    KAHN, RM
    ALPERT, ML
    GINSBERG, BP
    GREENWAY, FL
    CITRON, DM
    AMERICAN JOURNAL OF MEDICINE, 1987, 82 (4A): : 284 - 287
  • [33] Cranberry versus placebo in the prevention of urinary infections in multiple sclerosis: a multicenter, randomized, placebo-controlled, double-blind trial
    Gallien, Philippe
    Amarenco, Gerard
    Benoit, Nicolas
    Bonniaud, Veronique
    Donze, Cecile
    Kerdraon, Jacques
    de Seze, Marianne
    Denys, Pierre
    Renault, Alain
    Naudet, Florian
    Reymann, Jean Michel
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (09) : 1252 - 1259
  • [34] Terazosin therapy for patients with female lower urinary tract symptoms: A randomized, double-blind, placebo controlled trial
    Low, Bee Yean
    Liong, Men Long
    Yuen, Kah Hay
    Chee, Christopher
    Leong, Wing Seng
    Chong, Wooi Loong
    Khan, Nurzalina Abdul Karim
    Cheah, Phaik Yeong
    Liong, Ker Keong
    JOURNAL OF UROLOGY, 2008, 179 (04): : 1461 - 1469
  • [35] ANTI-MICROBIAL PROPHYLAXIS OF RECURRENT URINARY-TRACT INFECTIONS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    STAMM, WE
    COUNTS, GW
    WAGNER, KF
    MARTIN, D
    GREGORY, D
    MCKEVITT, M
    TURCK, M
    HOLMES, KK
    ANNALS OF INTERNAL MEDICINE, 1980, 92 (06) : 770 - 775
  • [36] ORAL IMMUNOTHERAPY IN PARAPLEGIC PATIENTS WITH CHRONIC URINARY-TRACT INFECTIONS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    HACHEN, HJ
    JOURNAL OF UROLOGY, 1990, 143 (04): : 759 - 763
  • [37] Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial
    Lorenz Leitner
    Wilbert Sybesma
    Nina Chanishvili
    Marina Goderdzishvili
    Archil Chkhotua
    Aleksandre Ujmajuridze
    Marc P. Schneider
    Andrea Sartori
    Ulrich Mehnert
    Lucas M. Bachmann
    Thomas M. Kessler
    BMC Urology, 17
  • [38] Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial
    Gupta, Varsha
    Mastromarino, Paola
    Garg, Ritu
    CLINICAL INFECTIOUS DISEASES, 2024, 78 (05) : 1154 - 1161
  • [39] Applicability of Press Needles to a Double-blind Trial A Randomized, Double-blind, Placebo-controlled Trial
    Miyazaki, Shougo
    Hagihara, Akihito
    Kanda, Ryo
    Mukaino, Yoshito
    Nobutomo, Koichi
    CLINICAL JOURNAL OF PAIN, 2009, 25 (05): : 438 - 444
  • [40] Topical heparin for the treatment of acute superficial phlebitis secondary to indwelling intravenous catheter A double-blind, randomized, placebo-controlled trialA double-blind, randomized, placebo-controlled trial
    M. Villardell
    D. Sabat
    J. A. Arnaiz
    M. J. Bleda
    J. M. Castel
    J. R. Laporte
    C. Vallvé
    European Journal of Clinical Pharmacology, 1999, 54 : 917 - 921